Neo Ivy Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Neo Ivy Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$320K	Buy	2,682 +2,502	+1,390%	+$293K	0.22%	191
2022 Q3	$19K	Buy	+180	New	+$18.3K	0.05%	300
2022 Q2	–	Sell	-2,216	Closed	-$208K	–	542
2022 Q1	$208K	Buy	2,216 +232	+12%	+$19.7K	0.19%	190
2021 Q4	$169K	Buy	+1,984	New	+$183K	0.24%	155
2021 Q3	–	Sell	-143	Closed	-$14K	–	574
2021 Q2	$14K	Buy	+143	New	+$13.7K	0.01%	382
2020 Q4	–	Sell	-3,884	Closed	-$373K	–	527
2020 Q3	$373K	Buy	+3,884	New	+$449K	0.38%	90
2020 Q2	–	Sell	-1,397	Closed	-$121K	–	550
2020 Q1	$121K	Sell	1,397 -2,146	-61%	-$210K	0.2%	195
2019 Q4	$381K	Buy	+3,543	New	+$371K	0.44%	95
2019 Q1	–	Sell	-6,499	Closed	-$464K	–	366
2018 Q4	$464K	Buy	+6,499	New	+$623K	0.37%	124

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neo Ivy Capital Management's NBIX Position: Q4 2022 in Review

Neo Ivy Capital Management increased its Neurocrine Biosciences (NBIX) stake by 1,390% in Q4 2022, buying an estimated $293K and bringing the position to 2,682 shares worth $320K. The position accounts for 0.22% of the portfolio, ranked #191.

Neo Ivy Capital Management first reported a position in NBIX in Q4 2018 and has held it in 9 quarters since. The position peaked at $464K in Q4 2018. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

Neo Ivy Capital Management held 2,682 shares of Neurocrine Biosciences worth $320K as of Q4 2022.
Neo Ivy Capital Management bought 2,502 Neurocrine Biosciences shares in Q4 2022, an estimated $293K.
Neurocrine Biosciences made up 0.22% of Neo Ivy Capital Management's portfolio in Q4 2022, its #191 holding.
Neo Ivy Capital Management first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 9 quarters since.
Neo Ivy Capital Management's Neurocrine Biosciences position peaked at $464K in Q4 2018.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Neo Ivy Capital Management's 13F filing for Q4 2022, filed 27 Mar 2023.